Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting
Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, today announced that new data from its lead development program, VTX-801 a novel investigational gene therapy for WD, and VTX-803, Vivet’ novel therapeutic in development for the treatment of PFIC3, have been accepted for oral presentation during the ASGCT 22nd Annual Meeting, April 29 - May 2, 2019 in Washington, D.C., USA.
Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the
Gene Therapy Dept. at FIMA will present data from a recently completed
study, validating in WD mice the use of fecal excretion of IV-injected 64copper
as a pharmacodynamic endpoint in the VTX-801 Phase I/II trial currently
under preparation. These data are the first demonstration of copper
homeostasis restoration with 64Copper in an animal model of
WD through the delivery of a single, intravenous administration of AAV.
Title:
Preclinical Validation of
64
Copper as a
Translational Tool for Evaluating the Pharmacodynamics of VTX-801 Gene
Therapy in Wilson disease (Tuesday April 30 at 3:30-3:45pm / Room:
Heights Courtyard 2)
New findings from recently completed preclinical study of VTX-803 will be presented by Dr. Nicholas D. Weber, Research Scientist at Vivet. Dr Weber will present a new animal proof of concept study for VTX-803, one of Vivet’s portfolio indications: “AAV Expressing MDR3 (VTX-803) Mediates the Correction of Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3) in a Clinically Relevant Mouse Model” (Tuesday April 30 at 4:15-4:30pm / Room: Heights Courtyard 1). These data expand and confirm earlier observations.
The abstracts listed above has been accepted for an Oral Presentation and can be found online at: https://www.asgct.org/global/documents/asgct19_abstracts_-final
Vivet Therapeutics will also be presenting during the Wilson Disease Association (WDA) 2019 annual conference (May 3-4 / New York, USA) and at the Wilson Aarhus 2019 symposium (May 9-12 / Aarhus, Denmark).
About Vivet Therapeutics
Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.
Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada, University of Navarra based in Pamplona, Spain.
Vivet’s lead program, VTX-801, is a novel investigational gene therapy for Wilson disease which has been granted Orphan Drug Designation by the Food and Drug Administration and the European Commission.
Vivet is supported by international life science investors. For more information please visit us on www.vivet-therapeutics.com and follow us on Twitter at @Vivet_tx and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005418/en/
Contact information
Media & Investor contact:
Thomas Daniel-Robin
Business
Development Director
info@vivet-therapeutics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Missing Piece - TUC s.r.l presents TUC.tiny: the key to access New Mobility24.4.2024 10:35:00 EEST | Press release
TUC S.r.l., the Deep Tech Company known for TUC.technology, launches a fundamental evolution of its offer, TUC.tiny™. This mobility revolution comes with all the features at the base of the TUC.technology patent, issued in over 140 countries worldwide. A small jewel based on TUC's three technological pillars, mechanical structuring, electronic management and data exchange, designed to also interface with consumer electronics thanks to the integration of USB Type-C technology. TUC.tiny™ becomes the USB of Mobility, a solution that aims to reinvent the interaction between users and vehicles bringing together mobility and everyday life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424672317/en/ TUC dashboard (Photo: Business Wire) A real blank canvas, which can be transformed and customized countless times thanks to TUC.tiny™ and TUC.technology™, flexibly adapting to every need and preference. With TUC's innovative patente
Digital Health Leaders Meet at HIMSS24 Europe to Deliver Solutions to Tomorrow’s Healthcare Challenges24.4.2024 10:03:00 EEST | Press release
To address Europe’s most pressing healthcare challenges, Europe's longest-running, most influential digital health conference returns in 2024, bringing together innovators to shape tomorrow’s healthcare. The HIMSS24 European Health Conference & Exhibition will occur from 29-31 May at the Centro Congressi Roma La Nuvola in Rome, Italy. The conference will be the epicenter for pan-European collaborations and innovation, featuring thought leaders and healthcare professionals working together to create the best technology solutions across the digital health landscape. HIMSS24 Europe will feature programming focused on major global health challenges. Experts will lead discussions on how Europe uses data analytics, artificial intelligence, cybersecurity, and other cutting-edge technologies to address universal issues like health equity, patient privacy, access to care, workforce burnout, staffing shortages, and climate change. Registration is open for HIMSS24 Europe , and interested journali
Suzano Ventures invests up to US$5 million into Bioform Technologies to further develop bio-based plastic alternatives24.4.2024 10:01:00 EEST | Press release
Suzano Ventures, the corporate venture capital arm of Suzano, the world’s largest market pulp producer, has made a strategic investment into the Canadian materials science startup, Bioform Technologies. The investment provides up to US$5 million towards the company’s seed round, enabling it to accelerate the development of its novel bio-based plastic alternatives. The products can be manufactured through modified industrial processes already used in the pulp and paper sector. Bioform’s proprietary technology rapidly produces wood pulp-reinforced hydrogels to create high-performance plastic alternatives, which can be made using Suzano’s wood pulp fibre as a key input. Bioform’s materials have the potential to be home compostable or recycled through existing paper recycling processes and do not require fossil-based inputs. The technology is highly versatile and has a number of applications where it could replace conventional single-use plastics, including paper recyclable thermoformable
Kalray Joins Arm Total Design, Extending Collaboration With Arm on Accelerated AI Processing24.4.2024 10:01:00 EEST | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge, announced that it has extended its collaboration with Arm by joining Arm Total Design. Through a deeper connection to industry leaders who are leveraging Arm® Neoverse™ Compute Subsystems (CSS), Kalray can help more companies integrate its unique AI and data acceleration technology and help Arm ecosystem partners commercialize AI-based solutions in a fraction of the time and cost usually needed. Arm Total Design helps accelerate and simplify the delivery of custom silicon based on Arm Neoverse CSS and has grown to more than 20 partners, including the top three leading foundries, ASIC design houses, IP vendors, EDA tool providers, and firmware developers who are driving leading-edge innovation. Kalray is already working to integrate Arm Coherent Mesh Network (CMN) technology to help easily connect Kalray’s advanced AI and data processing
SES’s O3b mPOWER System Starts Providing High-performance Connectivity Services24.4.2024 09:50:00 EEST | Press release
SES announced today that O3b mPOWER, its second-generation software-enabled satellite system, is now operational and can provide high-performance connectivity services around the globe. With the first six O3b mPOWER satellites operating at medium Earth orbit (MEO) or 8,000km away from the Earth and with extensive ground infrastructure built around the world, SES will be introducing services in the coming months to O3b mPOWER customers to deliver reliable connectivity services ranging from tens of Mbps to multiple gigabits per second. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423122963/en/ SES’s O3b mPOWER System Starts Providing High-performance Connectivity Services (Photo: Business Wire) To date, SES has launched six out of 13 O3b mPOWER high-throughput and low-latency satellites, which together with strategically located satellite ground stations, enable SES to serve customers across multiple market segments aroun
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom